Transarterial Chemoembolization using Idarubicin versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma (IDADOX)

Seoul National University Hospital0 个研究点目标入组 128 人开始时间: 待定最近更新: 2023年6月26日

适应症

试验速览

暂无简介。

•a.Age > 18 years
•b.Histologically or radiologically (LI-RADS 4 or 5) diagnosed as hepatocellular carcinoma
•c.Tumor number = 5
•d.Largest tumor diameter = 5 cm
•e.Treatment-naïve patient
•f.Child-Pugh class A or B
•g.Eastern Cooperative Oncology Group performance status = 2
•h.No severe impairment of major organs (Blood tests performed within one month of the procedure must satisfy all of the following findings)
•- WBC count = 12,000 / mm3
•- Absolute neutrophil count = 1,500 /mm3
•- Hemoglobin = 8.0 g/dL
•- Total bilirubin = 3.0 mg/dL
•- eGFR = 30 mL/min/1.73 m2
•i.Patients for whom conventional transarterial chemoembolization was determined as the optimal treatment after hepatologists', hepatic surgeons' or multidisciplinary clinics.
•j.Patients who fully understand and agree to participate in this clinical trial in writing
•k.Patients with effective contraception for at least 6.5 months post-treatment for women with childbearing age, and 3.5 months post-treatment for men with partners with childbearing age

•a.Hepatocellular carcinoma with vascular invasion
•b.Hepatocellular carcinoma with extrahepatic spread
•c.Patients with active cancer other than hepatocellular carcinoma within 2 years from the enrollment
•d.Patients with previous biloenteric anastomosis surgery.
•e.Patients contraindicated to the use of idarubicin or doxorubicin

发起方